Literature DB >> 23616957

Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease.

Carmen Stolwijk1, Marieke Pierik, Robert Landewé, Ad Masclee, Astrid van Tubergen.   

Abstract

BACKGROUND: Musculoskeletal symptoms belonging to the spectrum of 'seronegative spondyloarthritis' (SpA) are the most common extraintestinal manifestations in patients with inflammatory bowel disease (IBD) and may lead to important disease burden. Patients with suspected SpA should be referred to a rheumatologist for further evaluation.
OBJECTIVE: To investigate the self-reported prevalence of musculoskeletal SpA features in a cohort of patients with IBD and to compare this with actual referrals to a rheumatologist.
METHODS: Consecutive patients with IBD visiting the outpatient clinic were interviewed by a trained research nurse about possible SpA features using a standardized questionnaire regarding the presence or history of inflammatory back pain, peripheral arthritis, enthesitis, dactylitis, psoriasis, uveitis and response to nonsteroidal anti-inflammatory drugs. All patient files were verified for previous visits to a rheumatologist and any rheumatic diagnosis.
RESULTS: At least one musculoskeletal SpA feature was reported by 129 of 350 (36.9%) patients. No significant differences between patients with Crohn disease and ulcerative colitis were found. Review of medical records showed that 66 (51.2%) patients had ever visited a rheumatologist. Axial SpA was diagnosed in 18 (27.3%) patients, peripheral SpA in 20 (30.3%) patients and another rheumatic disorder in 14 (21.2%) patients.
CONCLUSION: Musculoskeletal SpA features are frequently present in patients with IBD. However, a substantial group of patients is not evaluated by a rheumatologist. Gastroenterologists play a key role in early referral of this often debilitating disease.

Entities:  

Mesh:

Year:  2013        PMID: 23616957      PMCID: PMC3742476          DOI: 10.1155/2013/139702

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  51 in total

1.  The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study).

Authors:  Ø Palm; B Moum; J Jahnsen; J T Gran
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

2.  Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study).

Authors:  Oyvind Palm; Bjørn Moum; Aksel Ongre; Jan Tore Gran
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

3.  Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease.

Authors:  Hans Herfarth; Florian Obermeier; Tilo Andus; Gerhard Rogler; Susanna Nikolaus; Tanja Kuehbacher; Stefan Schreiber
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

4.  Can some cases of 'possible' spondyloarthropathy be classified as 'definite' or 'undifferentiated' spondyloarthropathy? Value of criteria for spondyloarthropathies. Spanish Spondyloarthropathy Study Group.

Authors:  E Collantes; R Veroz; A Escudero; E Muñoz; M C Muñoz; A Cisnal; V Perez
Journal:  Joint Bone Spine       Date:  2000       Impact factor: 4.929

5.  Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms.

Authors:  F Van den Bosch; E Kruithof; M De Vos; F De Keyser; H Mielants
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

6.  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.

Authors:  K de Vlam; H Mielants; C Cuvelier; F De Keyser; E M Veys; M De Vos
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

7.  Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients.

Authors:  C Salvarani; I G Vlachonikolis; D M van der Heijde; G Fornaciari; P Macchioni; M Beltrami; I Olivieri; F Di Gennaro; P Politi; R W Stockbrügger; M G Russel
Journal:  Scand J Gastroenterol       Date:  2001-12       Impact factor: 2.423

8.  How to diagnose axial spondyloarthritis early.

Authors:  M Rudwaleit; D van der Heijde; M A Khan; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

9.  The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort.

Authors:  Martin Rudwaleit; Hildrun Haibel; Xenofon Baraliakos; Joachim Listing; Elisabeth Märker-Hermann; Henning Zeidler; Jürgen Braun; Joachim Sieper
Journal:  Arthritis Rheum       Date:  2009-03

10.  Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Authors:  M Rudwaleit; J Listing; J Brandt; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-03-22       Impact factor: 19.103

View more
  16 in total

1.  IBD: IBD and spondyloarthritis: joint management.

Authors:  Paolo Gionchetti; Fernando Rizzello
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-16       Impact factor: 46.802

2.  Multidisciplinary teams as standard of care in inflammatory bowel disease.

Authors:  Subrata Ghosh
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

3.  Low Back Pain and Sacroiliitis on Cross-Sectional Abdominal Imaging for Axial Spondyloarthritis Diagnosis in Inflammatory Bowel Diseases.

Authors:  Marine Fauny; Nicolas Cohen; Caroline Morizot; Sophie Leclerc-Jacob; Daniel Wendling; Guillaume Lux; Valérie Laurent; Alain Blum; Patrick Netter; Cédric Baumann; Isabelle Chary-Valckenaere; Laurent Peyrin-Biroulet; Damien Loeuille
Journal:  Inflamm Intest Dis       Date:  2020-06-03

Review 4.  Role of capsule endoscopy in inflammatory bowel disease.

Authors:  Uri Kopylov; Ernest G Seidman
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 5.  Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations.

Authors:  Edouard Louis; Iris Dotan; Subrata Ghosh; Liat Mlynarsky; Catherine Reenaers; Stefan Schreiber
Journal:  J Crohns Colitis       Date:  2015-05-18       Impact factor: 9.071

6.  Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study.

Authors:  Abigail Hensley; Ian L P Beales
Journal:  Pharmaceuticals (Basel)       Date:  2015-09-07

7.  Relationship between articular and nonarticular manifestations in inflammatory bowel diseases.

Authors:  Alimohammad Fatemi; Hourossadat Hashemi Jazi; Mohammad Hasan Emami; Amir Kazemizadeh; Hamid Tavakkoli; Abbas Smiley
Journal:  J Res Med Sci       Date:  2016-06-14       Impact factor: 1.852

8.  Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.

Authors:  Michele Maria Luchetti; Devis Benfaremo; Francesco Ciccia; Laura Bolognini; Monia Ciferri; Alessia Farinelli; Matteo Rossini; Piergiorgio Mosca; Giovanni Triolo; Armando Gabrielli
Journal:  World J Gastroenterol       Date:  2017-10-21       Impact factor: 5.742

Review 9.  Capsule Endoscopy for Ileitis with Potential Involvement of Other Sections of the Small Bowel.

Authors:  Hyun Seok Lee; Yun Jeong Lim
Journal:  Gastroenterol Res Pract       Date:  2016-01-12       Impact factor: 2.260

Review 10.  Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.

Authors:  Gerhard Rogler; Abha Singh; Arthur Kavanaugh; David T Rubin
Journal:  Gastroenterology       Date:  2021-08-03       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.